Browsing by author "Gore, Martin"
Now showing items 1-11 of 11
-
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer.
Del Campo, JM; Birrer, M; Davis, C; Fujiwara, K; Gollerkeri, A; et al. (2016-07)Objective PF-04691502 and gedatolisib (PF-05212384) are potent, dual PI3K/mTOR inhibitors. This phase II study (B1271004) was conducted in patients with recurrent endometrial cancer following platinum-containing chemotherapy. ... -
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie, PG; Marshall, A; Nathan, PD; Lorigan, P; Gore, M; et al. (2018-08)Background Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma ... -
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii, S; Gourley, C; Kumar, R; Geuna, E; Ern Ang, J; et al. (2017-07)Background The PARP inhibitor olaparib was recently granted Food and Drug Administration (FDA) accelerated approval in patients with advanced BRCA1/2 mutation ovarian cancer. However, antitumor responses are observed in ... -
Caelyx-induced unilateral erythrodysesthaesia secondary to venous thromboembolism.
Merika, EE; Gore, M; Fearfield, LA (2017-06) -
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Oza, A; Kaye, S; Van Tornout, J; Sessa, C; Gore, M; et al. (2018-05)BACKGROUND:Linsitinib, an oral, dual inhibitor of insulin-like growth factor-1 receptor and insulin receptor, in combination with weekly paclitaxel, may improve clinical outcomes compared with paclitaxel alone in patients ... -
Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib.
Seifert, H; Fisher, R; Martin-Liberal, J; Edmonds, K; Hughes, P; et al. (2016-04)The BRAF inhibitor vemurafenib is an effective drug in patients with BRAF mutant metastatic melanoma, but resistance occurs after a median of 6 months. The anti-CTLA4-antibody, ipilimumab, is a standard first-line and ... -
Rare non-epithelial ovarian neoplasms: Pathology, genetics and treatment.
Foulkes, WD; Gore, M; McCluggage, WG (2016-07)Rare non-epithelial ovarian neoplasms have posed management challenges for many years. Their rarity means that most specialist practitioners will see one such case every several years, and most generalists may never see a ... -
Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study.
Gore, ME; Jones, RJ; Ravaud, A; Kuczyk, M; Demkow, T; et al. (2017-06)Objective To assess the efficacy and safety of sorafenib dose escalation in metastatic renal cell carcinoma (mRCC).Patients and methods Intra-patient dose escalation may enhance the clinical benefit of targeted anticancer ... -
Sunitinib in the treatment of metastatic renal cell carcinoma.
Schmid, TA; Gore, ME (2016-12)Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard ... -
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.
Wang, Y; Bernhardy, AJ; Cruz, C; Krais, JJ; Nacson, J; et al. (2016-05)Breast and ovarian cancer patients harboring BRCA1/2 germline mutations have clinically benefitted from therapy with PARP inhibitor (PARPi) or platinum compounds, but acquired resistance limits clinical impact. In this ... -
The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2).
Matz, M; Coleman, MP; Sant, M; Chirlaque, MD; Visser, O; et al. (2017-02)Objective Ovarian cancers comprise several histologically distinct tumour groups with widely different prognosis. We aimed to describe the worldwide distribution of ovarian cancer histology and to understand what role this ...